

HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Potassium Removing Agents

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

1 == 10 = 110 1 = 1 7 mg morniadon (padont, pro-	orribor, arag, labo	, iore blank, mogibio, or not a	taonoa mill blant the forten process.	
Patient Name:		Prescriber Name:		
HPP Member Number:		Fax:	Phone:	
Date of Birth:		Office Contact:		
Patient Primary Phone:		NPI:	PA PROMISe ID:	
Address:		Address:		
City, State ZIP:		City, State ZIP:		
Line of Business: ☐ Medicaid ☐ CHIP		Specialty Pharmacy (if applicable):		
Drug Name:		Strength:		
Quantity:		Refills:		
Directions:		- TOTHIO		
Diagnosis Code:	Diagnosis:			
HPP's maximum approval time is 12 months but may be less depending on the drug.				
The Chiakiman approval and to 12 monate sactinal so look deponding on the drag.				
Please attach any pertinent medical history including labs and information for this member that may support approval.				
Please answer the following questions and sign.				
Q1. Is the requested drug being prescribed by or in consultation with a cardiologist or nephrologist?				
☐ Yes ☐ No				
Q2. Is the requested drug being prescribed at a dose that is consistent with Food and Drug Administration (FDA)				
approved package labeling, nationally recognized compendia, or peer-reviewed medical literature?				
☐ Yes ☐ No				
Q3. Is this a request for a renewal of authorization?				
Yes		□ No		
Q4. Does the patient have documentation of recent serum potassium levels demonstrating a positive clinical response to therapy?				
☐ Yes ☐ No				
Q5. Is the patient being treated for a diagnosis that is indicated in the Food and Drug Administration (FDA) approved package labeling OR a medically accepted indication?				
☐ Yes		□ No		
Q6. Is the requested drug age-appropriate according to Food and Drug Administration (FDA) approved package labeling, nationally recognized compendia, or peer-reviewed medical literature?				
Yes		□No		
Q7. Does the patient have documentation of hyperkalemia?	of recent serun	n potassium levels consi	stent with a diagnosis of	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Potassium Removing Agents

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:		
☐ Yes	□ No		
Q8. Does the patient have documented failure of ALL of t A) a low potassium diet, B) a loop or thiazide diuretic (if clinically appropriate), C) discontinuation or dose reduction to the minimum effect			
☐ Yes	□ No		
Q9. Is this a request for a preferred potassium removing agent?			
☐ Yes	□ No		
Q10. Does the patient have a history of therapeutic failure potassium removing agents?	e, contraindication to, or intolerance of the preferred		
☐ Yes	□ No		
Q11. Additional Information:			
Prescriber Signature	Date		

Updated for 2023